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use#LAAThe problem of diabetes: prospects for 
stem‑cell‑based approaches
The  promise  of  stem-cell-derived  therapies  holds 
particularly high hopes for diabetes. The prevalence of 
both type 1 and type 2 diabetes continues to climb and 
their complications are devastating. In type 1 diabetes, 
the  beta  cells  are  decimated  by  autoimmunity  and  for 
unknown reasons the disease is being seen more often. 
Type 2 diabetes accounts for over 95% of diabetes cases 
worldwide  and  its  increase  is  mainly  caused  by  the 
encroachment of Western lifestyles of poor diet and lack 
of  exercise,  leading  to  insulin  resistance  and  obesity. 
Advances in genomics and other fields have produced a 
dramatic generation of new knowledge that enhances our 
understanding of the pathogenesis of all forms of diabetes 
and provides exciting new avenues for treatment.
The potential of stem cell approaches for diabetes is 
particularly attractive because the development of both 
forms  of  diabetes  is  dependent  upon  deficiency  of 
pancreatic  beta  cells,  and  the  diabetic  state  can  be 
reversed using beta cell replacement therapy. For type 1 
diabetes  this  concept  is  supported  by  the  success  of 
pancreas  and  islet  transplantation  [1,2].  For  type  2 
diabetes, the potential of beta cell replacement is less well 
understood because so much focus has been on insulin 
resistance,  which  is  certainly  an  important  therapeutic 
target.  However,  most  people  with  insulin  resistance 
never  progress  to  the  diabetic  state.  Those  who  do 
progress to type 2 diabetes have reduced beta cell mass, 
which is typically 40% to 60% of normal, as determined 
by autopsy studies [3]. Moreover, normal glucose levels 
can  be  restored  in  type  2  diabetes  using  beta  cell 
replacement in the form of pancreas transplantation [4]. 
The  progression  of  complications  to  the  eyes,  kidneys 
and  nerves  can  be  largely  halted  by  prevention  of 
hyperglycemia  [5].  Therefore,  advances  in  stem  cell 
biology have the potential to make beta cell restoration 
possible as an approach for both forms of diabetes.
There are also other ways in which stem cell biology 
might be helpful for diabetes. For example, there is great 
interest in mesenchymal stromal cells and the possibility 
that  they  could  modulate  autoimmunity  or  somehow 
promote islet cell regeneration [6]. Stem cell approaches 
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modulate the immune system to prevent killing of beta 
cells. With regard to type 2 diabetes, work on stem cells 
might lead to innovative approaches to the problems of 
obesity  and  insulin  resistance.  In  addition,  stem  cell 
science could be applied to treat diabetic complications 
such as atherosclerosis and microvascular disease. Equally 
as  important,  the  prospect  of  obtaining  induced 
pluripotent stem (iPS) cells from individuals with various 
forms of diabetes has recently opened up opportunities 
to study the individual cell types that are important in 
pathogenesis [7]. In this review, we discuss many of these 
opportunities and highlight how advances in genomics 
and other disciplines have advanced these endeavors.
Understanding the genetics of diabetes through 
genomics
Type 1 diabetes
This form of diabetes is caused by a complex combination 
of  genetic  and  environmental  factors  [8].  Finding  that 
only  about  50%  of  identical  twins  are  concordant  for 
diabetes highlights the importance of the environment. 
The most important genetic contribution, which accounts 
for about 50% of the genetic influence, comes from the 
locus containing the HLA class II genes. The next most 
important  locus  is  that  of  the  insulin  (INS)  VNTR 
(variable  number  of  tandem  repeats),  which  is  of 
considerable interest because insulin has been proposed 
as the key antigen initiating the process of autoimmunity 
[9].  Further  advances  in  genetics,  most  notably  high-
density genome-wide association studies (GWAS), have 
led to the identification of over 40 loci associated with 
type 1 diabetes [10]. All of these associations are weak 
but  the  influence  of  an  individual  gene  is  likely  to  be 
important in a particular family, probably even more so 
when combined with the effects of other genes. Loci of 
special  interest  also  include  genes  encoding  cytotoxic 
T-lymphocyte-associated  protein  4  (CTLA4),  protein 
tyrosine  phosphatase-22  (PTPN22),  and  IL2  receptor 
alpha (IL2A).
Type 2 diabetes
This is far and away the most common form of diabetes. 
It  has  long  been  known  to  be  strongly  determined  by 
genetics, as evidenced by numerous family studies, but 
finding the responsible genes has proved to be extremely 
difficult. Now GWAS have identified more than 40 loci 
associated with the disease [10]. The surprise to many 
was that most of these loci contained genes related to 
beta  cell  development  and  function,  and  relatively  few 
were linked to insulin resistance and obesity. However, a 
central role for beta cell failure is now accepted to be an 
essential part in the pathogenesis of type 2 diabetes [11]. 
A problem is that the associations with type 2 diabetes 
are very weak for all of these implicated genes and loci, 
and even taken collectively they are thought to account 
for  only  about  10%  of  the  genetic  influence  [10]. 
Therefore, at present they have limited value in predicting 
susceptibility [12].
Monogenic diabetes
Diabetes caused by a single gene mutation has also been 
called  maturity-onset  diabetes  of  the  young  (MODY) 
[13,14]. The best-described forms, all inherited as auto-
somal dominant genes, are described in Table 1, but new 
versions and variants of MODY continue to be identified. 
Almost all forms of MODY are attributable to mutations 
that  result  in  deficient  insulin  release  and  are  not 
associated with insulin resistance.
Pancreatic beta cells: transcriptional networks, 
epigenetics and microRNAs
Because of their central role in diabetes, it is important to 
appreciate the characteristics of pancreatic beta cells [15] 
(Box 1). Many studies have provided good descriptions of 
these well-characterized cells, but the important point is 
that beta cells should be able to store and secrete insulin 
in an extraordinarily efficient manner. To keep glucose 
levels  in  the  normal  range  with  meals  and  exercise, 
increases  and  decreases  in  insulin  secretion  must  be 
rapid and precise.
Thanks to advances in embryology, genomics and other 
techniques  there  has  been  extraordinary  progress  in 
understanding  how  beta  cells  develop  and  function. 
Much is now known about how definitive endoderm is 
Table 1. Some forms of monogenic or maturity‑onset 
diabetes of the young
Type  Protein  Description
MODY 1  HNF4A  Loss-of-function mutations
MODY 2  Glucokinase  Many forms, most often mild diabetes,  
    can cause hypoglycemia
MODY 3  HNF1A  Loss-of-function mutations
MODY 4  PDX1  Pancreas atrophy and beta cell  
    impairment
MODY 5  HNF1B  Pancreas atrophy and renal disease
MODY 6  NeuroD1  Transcription factor important for beta  
    cell development
Permanent   KCNJ11,   Can be associated with hypoglycemia 
neonatal   ABCC8,   or diabetes. Some forms can be treated 
diabetes  neurogenin 3  with sulfonylureas 
Transient   ABCC8  Some forms remit with time 
neonatal  
diabetes
ABCC8, ATP-binding cassette, sub-family C, member 8; HNF1A, hepatocyte 
nuclear factor 1 homeobox A; HNF1B, hepatocyte nuclear factor 1 homeobox 
B; HNF4A, hepatocyte nuclear factor 4 alpha; KCNJ11, potassium channel 
J11; MODY, maturity-onset diabetes of the young; NeuroD1, neurogenic 
differentiation factor 1; PDX1, pancreatic duodenal homeobox.
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of the gut-tube and then to development of the exocrine 
and endocrine pancreas, as has been reviewed recently 
[16]. The roles of various key transcription factors have 
been  identified,  and  now  their  place  in  transcriptional 
networks  is  being  defined.  Almost  20  years  ago,  the 
pancreatic duodenal homeobox (Pdx1) was found to be 
essential for pancreas development [17], and now we can 
better appreciate its complex contributions. For example, 
it  plays  a  key  role  in  the  expression  of  neurogenin  3 
(Ngn3), which is essential for the formation of all islet cell 
types. To activate Ngn3, Pdx1 appears to act in concert 
with  four  other  transcription  factors,  namely  one  cut 
homeobox 1 (Hnf6), SRY-box containing gene 9 (Sox9), 
Hnf1b and forkhead box A2 (Foxa2) [18]. Another key 
transcription  factor  is  Rfx6,  a  member  of  the  RFX 
(regulatory factor X-box binding) family, which functions 
downstream of Ngn3 and is essential for the formation of 
all islet cell types except pancreatic polypeptide-produc-
ing cells [19]. Currently, there is considerable focus on 
the final stages of beta cell maturation and the large Maf 
transcription factors are of particular interest. Immature 
beta cells produce MafB and as they mature they switch 
to MafA production, which appears to be important for 
optimal glucose-stimulated insulin secretion [20].
Advances  in  epigenetics  and  microRNA  studies  have 
now  made  our  understanding  of  transcriptional  control 
even more complicated. These fields are still young but are 
proving to be important. Regulation of gene expression is 
highly  influenced  by  chromatin  remodeling,  either  by 
modi  fication  of  histones  or  by  methylation  of  DNA. 
Histone modification can occur by acetylation, methyla-
tion,  ubiquitylation,  phosphorylation  or  sumoylation. 
Methylation of DNA occurs mostly at CpG sites with the 
conversion of cytosine to 5-methylcytosine. An impor-
tant insight into the epigenetic control of insulin gene 
expression  came  from  the  observation  in  human  islets 
that a surprisingly large region of about 80 kb around the 
insulin  gene  is  very  enriched  with  marks  of  histone 
acetylation and H3K4 dimethylation [21]. Because insulin 
is  the  most  important  product  of  beta  cells,  it  is  not 
surprising  that  control  of  its  expression  would  require 
elaborate  mechanisms.  Another  interesting  finding  is 
that repression of the gene aristaless-related homeobox 
(Arx) caused by DNA methylation is critical for main-
taining beta cell phenotype [22]. Continued production 
of Arx would result in a pancreatic alpha cell phenotype.
Next-generation sequencing approaches have also started 
to  provide  important  insights.  Chromatin  immuno-
precipitation  and  parallel  sequencing  (ChiP-seq)  tech-
nology has been used to study histone marks in human 
islets [23]. That study focused on H3K4me1, H3K4me2 
and H3K4me3, which are associated with transcription 
activation, and H3K27me3, which is associated with gene 
repression. There were expected findings and surprises. 
As predicted, some genes with repressed expression were 
enriched in H3K27me3. These included NGN3, which is 
critical for the development of islet cells, and HOX genes, 
which are important for early development. As expected, 
PDX1 was highly expressed in beta cells and was asso-
ciated  with  enrichment  of  H3kme1.  Surprisingly,  how-
ever, for both insulin and glucagon genes, there was a 
paucity of activation markers.
Important  roles  for  microRNAs  in  diabetes  are  also 
now  starting  to  be  understood  [24].  There  has  been 
particular  interest  in  microRNA-375,  which  is  highly 
expressed in beta cells, and when knocked out in mice 
leads to reduction in beta cell mass and diabetes [25]. In 
addition, it has recently been shown that a network of 
microRNAs has a strong influence on insulin expression 
in beta cells [26].
Pancreatic beta cells in diabetes
Beta  cells  undergo  many  complex  changes  during  the 
progression of diabetes, and these are beyond the scope 
of  this  review.  However,  a  gradual  decline  in  beta  cell 
mass  is  fundamental  to  the  development  of  type  2 
diabetes.  Many  mechanisms  for  the  decline  have  been 
proposed,  and  these  include  endoplasmic  reticulum 
stress,  toxicity  from  amyloid  formation  and  oxidative 
stress, but the problem remains poorly understood [11]. 
It is also important to point out that as beta cell mass falls 
during the progression of type 2 diabetes, glucose levels 
rise, and beta cells in this environment of hyperglycemia 
Box 1. Characteristics of pancreatic beta cells
Synthesize and store large amounts of insulin  
(about 20 pg per cell)
Convert proinsulin to insulin and C-peptide with over 
95% efficiency
Equimolar secretion of insulin and C-peptide
Secrete insulin in response to glucose with a biphasic pattern
Rapid secretory responses; increase or shut-off in less than 
3 minutes
Responses to a variety of agents: for example, incretins, amino 
acids, catecholamines, acetylcholine and sulfonylureas
Unique transcription factor expression combination (Pdx1, MafA, 
Nkx6.1, Nkx2.2, Pax6, NeuroD1)
Unique pattern of metabolic pathways (glucokinase as a glucose 
sensor, minimal lactate dehydrogenase and gluconeogenesis; 
active mitochondrial shuttles: malate-aspartate, glycerol 
phosphate, pyruvate-malate and pyruvate-citrate)
MafA, Maf transcription factor A; NeuroD1, neurogenic 
differentiation factor 1; Nkx2.2, Nk2 homeobox 2; Nkx6.1, Nk6 
homeobox 1; Pax6, paired box 6; Pdx1, pancreatic duodenal 
homeobox.
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secretion and phenotypic changes [27]. This malfunction 
is attributed to ‘glucose toxicity’ and is reversible [27].
Successes and challenges for islet transplantation
The first successful transplantation of islet cells into the 
liver in 1989 established the proof-of-principle for cell 
transplantation in diabetic patients [28], which has been 
helpful  for  focusing  research  efforts  towards  this  chal-
leng  ing goal. We know from animal studies that islet cells 
can  function  well  in  a  variety  of  transplant  locations, 
including  subcutaneous  and  omental  sites.  Although 
challenging, even the pancreas remains a possibility as a 
transplant site. Interestingly, transplanted islet cells can 
function well even without maintaining their normal islet 
structure and vascularity [29].
The major challenges facing this approach are finding 
an  adequate  supply  of  islet  cells  and  preventing  trans-
planted or regenerated cells from being killed by immune 
destruction from autoimmunity and/or transplant rejec-
tion. Currently, islet transplants are performed using islets 
isolated from organ donor pancreases, but this supply will 
never be close to sufficient. Various approaches that might 
lead to an adequate supply of beta cells for replacement 
therapy can be found in Box 2.
Embryonic and induced pluripotent stem cells
It has already been shown that human embryonic stem 
cells (ESCs) can be directed to become fully mature beta 
cells. This feat was accomplished by Novocell, Inc. (now 
ViaCyte,  Inc.)  by  exploiting  what  was  known  about 
embryonic development and progress made with mouse 
ESCs  [30].  A  stepwise  approach  was  used  to  direct 
human ESCs towards islet cells, in which culture condi-
tions  were  coupled  with  sequential  addition  of  growth 
and differentiation factors that were able to drive ESC 
differentiation  to  definitive  endoderm,  gut-tube  endo-
derm,  pancreas  and  then  islet  cells.  It  was  possible  to 
generate cells in vitro that had characteristics of islet cells 
but  were  not  fully  mature.  However,  after  immature 
precursor cells were transplanted into immunodeficient 
mice, maturation progressed to produce beta cells that 
were  convincingly  normal  with  regard  to  multiple 
characteristics. Importantly, these cells could make and 
store fully formed insulin, release insulin in response to a 
glucose  stimulation,  and  could  cure  diabetes  in  mice. 
However,  much  further  research  is  needed  before  this 
advance  can  be  brought  to  clinical  application.  For 
example, there is concern that these populations of pre-
cursor cells might contain cells that will form teratomas. 
A current strategy involves transplanting cells within a 
planar  macroencapsulation  immunoprotective  device 
that  is  transplanted  under  the  skin  [31].  In  addition, 
investigators  are  working  to  obtain  full  maturation  in 
vitro. To find better ways to direct the development of 
ESCs into mature beta cells, there has been some success 
using a high-throughput screening approach to identify 
compounds that promote differentiation [32].
Efforts  to  direct  the  differentiation  of  iPS  cells  to 
mature islet cells are also progressing but have not yet 
had the success of ESCs [33]. There are concerns about 
the  epigenetic  changes  in  these  cells  and  this  is 
undergoing intense investigation. For example, there are 
now genome-wide reference maps of DNA methylation 
and  gene  expression  for  20  human  ESC  lines  and  12 
human iPS cell lines [34]. Such analyses make it possible 
to  better  understand  the  uniqueness  of  individual  cell 
lines. Similar genome-wide mapping of epigenetic marks 
has been carried out in mouse ESCs [35]. Studies also 
indicate that microRNAs promise to play important roles 
for understanding iPS cells, as evidenced by the demon-
stration that knockdown of three microRNAs interfered 
with reprogramming efficiency [36].
There are many practical issues about preparing beta 
cells from individuals using iPS cell technology, but at 
some point it should be possible to produce these at a 
reasonable cost. One major advantage for such generated 
beta  cells  is  that  they  would  not  be  faced  with  allo-
rejection. However, in the case of type 1 diabetes, these 
cells would be targets for autoimmunity and it would be 
necessary  to  develop  strategies  to  resist  this  immune 
assault. For type 2 diabetes, these cells could be trans-
planted into a variety of locations without concern about 
immune rejection.
Use of iPS cells to study disease pathogenesis
iPS  cells  could  also  be  an  exciting  way  to  study  the 
pathogenesis  of  diabetes  [7].  For  example,  for  type  1 
Box 2. Possible sources of beta cells for replacement 
therapy
Preparation of cells for transplantation
(a)  Embryonic or induced pluripotent stem cells
(b)  Adult stem/progenitor cells (islet neogenesis from duct 
cells or other precursor cells in the pancreas, or from 
non-pancreatic precursor cells)
(c)  Beta cell replication
(d)  Genetic engineering (conditional expression of specific 
genes in beta cells, or generation of cells that resist immune 
destruction)
(e)  Reprogramming (for example, acinar, liver, intestine, other)
(f)  Xenotransplants (porcine fetal, neonatal or adult; or other 
species)
Regeneration of the endocrine pancreas in vivo
(a)  Regeneration through stimulation of neogenesis, replication 
or reprogramming
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immunity by making iPS cells from affected individuals 
and  by  preparing  differentiated  cell  types  involved  in 
pathogenesis; these cell types include thymus epithelial 
cells, dendritic cells, various types of T cells or even the 
target, the beta cell. For type 2 diabetes, it would be of 
considerable  interest  to  study  beta  cells  from  subjects 
with the genetic associations found in GWAS [37]. Such 
beta  cells  could  also  be  of  great  value  to  the  pharma-
ceutical industry for testing new drugs.
Beta cell regeneration in the adult pancreas
There  have  been  hopes  that  it  might  be  possible  to 
replace  the  beta  cell  deficit  that  occurs  in  diabetes  by 
regenerating  new  beta  cells  from  adult  tissues.  The 
pancreas has received the most attention, in particular 
regarding  the  potential  for  replication  of  pre-existing 
beta cells or neogenesis. The term neogenesis is usually 
used  to  refer  to  the  formation  of  new  islets  in  the 
pancreas from a precursor cell other than islet cells [38]. 
While  there  could  be  stem  cells  in  the  pancreas  itself, 
observations  to  date  point  to  the  pancreatic  duct 
epithelium  as  the  most  likely  potential  source  for  new 
islet formation.
Beta cell replication
Rodent beta cells have an impressive capacity for replica-
tion, as has been shown using genetic models of insulin 
resistance [39] and in various models of partial beta cell 
destruction [40]. The major factor driving this replication 
appears to be glucose, which through its metabolism in 
beta cells turns on signals for growth [41]. Importantly, 
this  capacity  declines  with  age  [42].  The  situation  in 
humans  is  complex  in  that  replication  is  active  in 
neonatal life, allowing expansion of beta cell mass, but 
then  drops  markedly  in  childhood  [43].  In  most  adult 
humans,  the  rate  of  beta  cell  replication  as  studied  by 
markers  such  as  Ki67  or  other  methods  is  either  not 
measurable or very low [44-46]. Nonetheless, when islets 
are isolated from such individuals, a low rate of beta cell 
replication can be stimulated by high glucose and other 
agents [47]. Stimulation of replication is still considered 
to be an important therapeutic goal and progress is being 
made to understand the underlying cell cycle machinery 
[48].
Generation of beta cells from pancreatic alpha cells
Surprising results emerged after beta cells in mice were 
destroyed by genetically induced diphtheria toxin, in that 
some of the residual islet glucagon-secreting alpha cells 
appeared to assume a beta cell phenotype and were even 
able to restore glucose levels to normal. This occurred 
after many months [49]. However, it seems puzzling that 
there is little evidence that a similar process occurs when 
beta cells are killed by the toxin streptozocin; so many 
questions remain about the potential of this interesting 
phenomenon. It is of considerable interest that ectopic 
production of Pax4 in progenitor cells of mouse pancreas 
can lead to subsequent conversion of alpha cells to beta 
bells [50]. Further studies of pancreatic alpha cells will be 
needed  to  understand  their  potential  as  sources  for 
replacement of beta cell functions.
Neogenesis
It has been hypothesized that the process of postnatal 
neogenesis is a recapitulation of islet development in fetal 
life,  and  that  the  pancreatic  duct  epithelium  could  be 
stimulated therapeutically to make new islets [38]. One 
approach would be to develop a medication that would 
stimulate  the  process  of  neogenesis  within  a  patient’s 
pancreas.  Another  approach  would  involve  directed 
differentiation of duct cells into new islets in vitro that 
could then be transplanted [51,52]. There is still contro-
versy  about  neogenesis,  in  part  because  of  discrepant 
results  from  various  mouse  lineage-tracing  models 
[53-58],  but  there  is  support  for  the  concept  that  a 
population of duct cells could serve as multipotent pro-
genitors capable of generating new exocrine and endo-
crine  cells  [53].  Two  recent  papers  provide  further 
support for the presence of postnatal neogenesis, the first 
showing  it  occurs  in  the  neonatal  period  [59]  and  the 
second that it can occur after pancreatic injury [58]. In 
the  latter  paper,  when  both  acinar  and  islet  cells  were 
mostly  killed  by  diphtheria  toxin  produced  under  the 
control of the Pdx1 promoter, duct cells gave rise to both 
acinar and endocrine cells, with recovery of 60% of the 
beta cell mass and reversal of hyperglycemia. However, 
when  only  acinar  cells  were  killed  by  elastase-driven 
toxin, duct cells only gave rise to new acinar cells. It is 
our  view  that  in  adult  rodents,  the  most  significant 
regeneration comes from beta cell replication, but that 
neogenesis from ducts does occur, most notably in the 
neonatal period, and can be stimulated following some 
forms of pancreatic injury. The human pancreas is more 
difficult  to  study  but  there  are  data  suggesting  that 
neogenesis can make an important contribution to beta 
cell turnover during adult life [38,60].
Studies using rodent models have shown that various 
agents  (such  as  epidermal  growth  factor,  gastrin  and 
glucagon-like  peptide  1  agonists),  either  alone  or  in 
combination,  can  stimulate  neogenesis,  and  this  has 
raised  expectations  that  such  an  approach  might  be 
useful in humans [15]. Unfortunately, to date no evidence 
has emerged that these agents can increase beta cell mass 
in humans. However, it must be recognized that there is a 
need to develop better tools for measuring beta cell mass 
and that using insulin secretion to determine functional 
beta cell mass is only partially informative.
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While much attention has been paid to duct cells as the 
potential origin of new islets, there has also been a search 
for other stem cells or precursor cells. It has been possible 
to  clonally  derive  cells  from  pancreatic  cells  called 
pancreas-derived multipotent precursor cells that do not 
have ESC characteristics and can form neurosphere-like 
structures in vitro containing hundreds of cells [61]. The 
cells in these clusters, which can have either an islet cell 
or  a  neural  phenotype,  can  be  derived  from  dispersed 
cells  from  pancreas,  but  can  also  be  developed  from 
insulin-containing  cells  isolated  using  flow  cytometry. 
This raises questions as to whether beta cells themselves 
have  the  potential  to  transdifferentiate  into  stem  cells 
that are capable of regenerating even more beta cells. A 
different  cell  population  has  also  been  found  in  the 
pancreas of mice called very small embryonic-like stem 
cells [62]. Although these cells can differentiate to express 
some beta cell markers, their role in the pancreas and in 
other tissues remains to be defined.
Adult non‑pancreatic stem/precursor cells
Due to the need for beta cell replacement therapy, much 
work has been done in the past decade to generate beta 
cells  from  a  variety  of  cell  sources.  Some  of  the  most 
notable efforts have been with cells derived from bone 
marrow  and  amniotic  fluid  that  partially  differentiate 
with  manipulation  in  an  in  vitro  environment  [63,64]. 
Many experiments have also investigated whether various 
cells obtained from bone marrow turn into beta cells in 
the pancreas or in a transplant site using lineage tracing 
approaches, but these studies have been either uncon-
vinc  ing or negative [65,66]. A general approach has been 
to try to change the phenotype of various cell types in 
vitro  by  changing  the  environment  and  adding  growth 
and differentiation factors. It has been possible to direct 
such cells to express some beta cell markers and even 
some insulin, but there have been no convincing reports 
that true beta cells have been formed.
Reprogramming differentiated cells derived from endoderm
The reprogramming success of iPS cells has raised the 
possibility  that  cells  derived  from  endoderm,  such  as 
those in liver or exocrine pancreas, could be more easily 
converted to beta cells than cells from other embryonic 
origins. The hope is that someday reprogramming of liver 
or  exocrine  pancreas  could  be  accomplished  using 
adminis  tered factors (for example, by a simple injection 
technique). Liver is an appealing target because portions 
of  liver  could  be  more  easily  removed  than  pancreatic 
tissue, and then reprogrammed in vitro, whereupon the 
islet cells could be generated and then transplanted.
Considerable  effort  has  gone  into  reprogramming 
hepatocytes  and  biliary  epithelial  cells  by  introducing 
transcription factors such as Pdx1 and Ngn3 with viral 
vectors  [67-69].  There  has  been  success  in  generating 
cells with beta cell traits, including some insulin produc-
tion, but there is uncertainty about how many of these 
cells can be produced, how similar they are to beta cells, 
and how useful they might be in reversing the diabetic 
state.
More encouraging progress has been made by repro-
gram  ming pancreatic exocrine cells using adenoviruses 
carrying the transcription factors Pdx1, Ngn3 and MafA 
[70]. These cells had many characteristics of pancreatic 
beta  cells  with  regard  to  key  transcription  factors  and 
insulin  content,  and  they  could  partially  reverse  the 
diabetic state. Pdx1 is important for both early pancreatic 
and  islet  development.  Ngn3  is  essential  for  the 
specification of islet cells and MafA is needed for the final 
stages of beta cell maturation.
Mesenchymal stromal cells and hematopoietic stem cells
Mesenchymal  stromal  cells  (MSCs),  also  known  as 
mesen  chymal stem cells, have attracted a great deal of 
interest because of their potential to enhance regenera-
tion  of  beta  cells  and/or  modulate  autoreactivity  or 
alloreactivity  [6,71,72].  Making  progress  in  the  area  is 
difficult  because  MSCs  have  variable  phenotypes  and 
their actions and are not well understood. This is made 
even more complicated because many of these experi-
ments have used bone-marrow-derived cells, which can 
include both hematopoietic stem cells (HSCs) and MSCs. 
There is still little evidence that either HSCs or MSCs can 
be  converted  into  beta  cells.  However,  recent  data 
indicate  that  bone-marrow-derived  cells  can  enhance 
beta cell regeneration through as yet ill-defined mecha-
nisms [71]. Moreover, in the NOD mouse model of auto-
immune  diabetes,  MSCs  can  be  used  to  reverse  the 
diabetic state [73]. Also potentially important, mobilized 
HSCs  can  prolong  islet  allograft  survival  in  mice  [74]. 
There  have  been  a  large  number  of  clinical  trials 
employing MSCs, mostly for cardiovascular diseases, but 
little evidence for efficacy has emerged.
However, in one study, subjects with new-onset type 1 
diabetes were treated with autologous HSCs after con-
dition  ing with antithymocyte globulin and cyclophospha-
mide  [75].  Preservation  of  beta  cell  function  was 
impressive, but because of insufficient controls it is not 
possible to conclude that the efficacy had anything to do 
with the stem cells. It is also possible that the preservation 
of insulin secretion was entirely due to the strong (and, in 
our opinion, dangerous) level of immunosuppression that 
was employed.
Other stem‑cell‑based approaches
The focus of this review has been beta cell replacement, 
but  advances  in  stem  cell  research  might  eventually 
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It  is  possible  that  stem  cell  biology  might  be  used  to 
manipulate  the  immune  system  such  that  the  loss  of 
tolerance in type 1 diabetes can be restored. Perhaps it 
will be possible one day to direct adipocyte stem cells to 
make more energy-consuming brown fat, which could be 
useful for weight control [76]. Other strategies might lead 
to reduction of visceral adiposity, which contributes to 
insulin  resistance  and  vascular  disease.  Another 
possibility is that stem cells might also one day be used to 
regenerate kidney or retinal cells in diabetic patients, or 
to slow hyperglycemia-induced microvascular disease.
Stem cell tourism
In  spite  of  the  impressive  promise  of  stem  cells,  no 
proven  benefits  have  been  demonstrated  for  the  treat-
ment  of  diabetes.  Yet  many  people  with  diabetes  have 
received  stem  cell  treatments  that  have  not  been  fully 
investigated,  exposing  these  individuals  to  unneces  sary 
expense  and  potential  harm.  A  quick  search  of  the 
internet shows many websites that extol the benefits of 
stem cells for diabetes and many other diseases. There 
are  a  number  of  clinical  trials  underway  that  are  des-
cribed  on  the  website  Clinicaltrials.gov  [77].  Some  of 
these are well designed, will test important hypotheses 
and  have  good  safety  provisions.  However,  other  trials 
listed on the website may not employ rigorous science 
and may not be safe. Various responsible organizations 
are  providing  advice  to  people  in  search  of  stem  cell 
treatments.  In  particular,  the  International  Society  for 
Stem Cell Research devotes part of its website to provide 
information  and  guidelines  to  help  assess  purported 
treatments and clinical trials [78].
Conclusion and future perspectives
There  have  been  extraordinary  recent  advances  in  our 
understanding  of  diabetes  because  of  its  priority  as  a 
major health problem and the remarkable development 
of scientific methods in genomics, genetics, cell biology 
and other fields. In this review, we have described some 
of these advances and have focused upon ways in which 
stem cell research might lead the way to new therapies 
and paths to better understand the pathophysiology of 
the various forms of diabetes. There has been particular 
emphasis upon how stem cells might allow replenishment 
of the beta cell deficit that is such a fundamental part of 
diabetes, but there are also various ways in which stem cell 
research might help with the problems of auto  immunity, 
insulin  resistance  and  the  vascular  complica  tions  of 
diabetes.  Progress  with  stem  cell  biology  has  been 
impressive and prospects for the future are very exciting.
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